Roche Holding AG research snapshot
ROG AI stock analysis currently reads Roche Holding AG as a Swiss multinational healthcare company with dual leadership in pharmaceuticals and diagnostics, durable oncology franchise, strong free cash flow, and a moderate valuation. The analysis is not a certain price prediction. At the July 13, 2026 cutoff, the latest verified close for the ADR equivalent was $51.90, market capitalization was about $331.5 billion, and the main question was whether pipeline execution, diagnostics growth, and margin discipline can offset the biosimilar pressure on established cancer drugs and justify the current multiple. This is informational research and not investment advice.
Current price
$51.90 (ADR equivalent)
Market cap
$331.5 billion
AI score
72 / 100
Rating
Strong business with moderate entry valuation
Trend status
Range-bound near 50-day and 200-day moving averages
Data cutoff (updated weekly)
July 13, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Roche sells prescription pharmaceuticals and in-vitro diagnostics globally, with deep oncology expertise, a diversified diagnostics portfolio, and recurring revenue from chronic disease treatments and installed diagnostic equipment. | High |
| Moat | The moat comes from proprietary oncology drugs, Genentech biologics manufacturing, diagnostic instrument installed base, switching costs in hospital lab systems, patient-specific dosing IP, and a century-long brand in global healthcare. | High |
| Management | CEO Thomas Schinecker and Chairman Severin Schwan have maintained Roche leadership in oncology and diagnostics. Capital allocation has focused on bolt-on acquisitions (Carmot for obesity, Spark for gene therapy, Poseida for cell therapy), R&D reinvestment, and a consistent dividend. Key question is whether the obesity pipeline and diagnostics growth can offset biosimilar erosion. | Medium-high |
| Financial trend | 2024 revenue was CHF 62.39 billion with net income of CHF 9.19 billion. TTM revenue was about $63.36 billion on ADR basis with $12.88 billion net income. Operating cash flow remains strong, supported by diagnostics margin stability and pharmaceutical recurring sales. | High |
| Valuation | The ADR equivalent traded near 20.9x TTM earnings, 7.9x book value, and 5.2x revenue at the cutoff. The forward PE of 16.5x suggests modest earnings growth expectations, which is reasonable for a mature pharma with pipeline risk. | Medium |
| Technical trend | The ADR price was near the 50-day and 200-day moving averages with low ADX (8.95), indicating a range-bound, trendless pattern. RSI was neutral near 52. | Medium-high |
| Risk level | Key risks are biosimilar competition for established oncology drugs, late-stage pipeline failures, drug pricing regulation in Europe and US, Swiss franc strength, and the 2025 Lunsumio pricing dispute in Switzerland as a bellwether of industry pricing tension. | Medium-high |
| AI confidence | High confidence for the business map, audited financial data, market cap math, and major risk categories. Lower confidence for future stock returns, which depend on pipeline execution and multiple changes. | High data confidence |
| Investment certainty | Medium certainty. Roche is a defensible business with above-average pharma margins and diagnostics stability, but the stock price already reflects a good business and leaves limited room for upside surprises. | Medium |
ROG AI stock forecast
The ROG AI stock forecast uses scenario ranges around the $51.90 ADR cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires obesity pipeline success, diagnostics margin expansion, and reasonable pharma multiple. The base case assumes modest earnings growth with stable multiples. The bearish case assumes accelerated biosimilar erosion or pipeline setbacks.
$67 to $78
More likely if Roche obesity pipeline (CT-388, CT-996 from Carmot acquisition) progresses to late-stage trials, diagnostics growth accelerates, biosimilar erosion stabilizes, and the market assigns a higher forward PE to a reinvented growth profile.
$46 to $55
More likely if Roche delivers low-single-digit revenue growth, maintains operating margins through cost discipline, pipeline progresses steadily without blockbuster surprises, and the stock trades near a 17-18x forward PE.
$32 to $39
More likely if accelerated biosimilar erosion exceeds expectations, late-stage pipeline trials fail, drug pricing regulation tightens in Europe or the US, or the Swiss franc materially appreciates.
ROG AI technical analysis
ROG AI technical analysis starts from the $51.90 ADR closing price used for this July 13 static page. Barchart technical snapshots showed the ADR trading near its 50-day, 100-day, and 200-day moving averages, with RSI neutral and ADX below 10 indicating a weak or absent trend. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $51.90 | Latest verified ADR close used for this page as of the July 13, 2026 data cutoff. |
| Near support | $48.50 to $50.00 | The January 2026 and March 2026 swing low zone. A hold above this area keeps the longer consolidation intact. |
| Secondary support | $43.50 to $45.00 | The late 2023 and early 2024 reaction area. A sustained break below would weaken the technical structure significantly. |
| Near resistance | $53.50 to $55.00 | The May 2026 and June 2026 trading range highs. A breakout above this zone with volume would signal renewed upside momentum. |
| 50-day moving average | About $51.27 | Barchart showed the ADR slightly above its 50-day moving average around the cutoff, suggesting neutral near-term positioning. |
| 100-day moving average | About $51.97 | The 100-day MA was slightly above the current price, indicating limited short-term momentum. |
| 200-day moving average | About $50.37 | The ADR was slightly above the 200-day MA, supporting a neutral-to-slightly-positive long-term view. |
| Momentum | RSI 52.42, ADX 8.95 | RSI was neutral. ADX below 10 indicates a weak or absent directional trend. |
| Volume | About 1.6 to 2.3 million shares (ADR) | Average ADR volume has been declining from about 2.3M (200-day) to 1.6M (5-day). Low trend volume, not a breakout signal. |
| Volatility | ATR 14 near $1.16 (2.24%) | Position sizing should allow for normal daily movement of about 2.2% around the cutoff price. |
| Invalidation | Close below $48.50 or above $55.00 | A close below $48.50 would weaken the base case. A sustained close above $55.00 could signal a new uptrend. |
ROG AI trading strategy
The ROG AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels.
Look for ROG to hold above the $48.50 support zone and break above $55.00 with increasing ADR volume and improving ADX above 20 before treating an uptrend as confirmed.
A failed breakout or daily close below the 50-day area should reduce confidence in directional positioning.
If ROG pulls back toward $48.50 to $50.00 without a thesis break, evaluate the ~3% dividend yield and compare with Roche cash flow coverage and payout history.
Do not add solely because of the dividend. Review pipeline risk, biosimilar erosion, and Swiss franc exposure first.
Track Roche half-year and full-year results, Carmot obesity pipeline progress, diagnostics revenue growth, biosimilar erosion rates, drug pricing regulation, and the CHF/USD exchange rate.
Lower the rating if biosimilar erosion accelerates, late-stage pipeline trials fail, or the market re-rates European pharma to lower multiples.
Investment research summary
Roche turns drug discovery, clinical development, manufacturing, and diagnostics instrumentation into a diversified healthcare cash flow stream, anchored by oncology leadership and hospital lab relationships.
The moat is proprietary biologics manufacturing, oncology brand heritage, diagnostic instrument installed base, switching costs in hospital testing workflows, and Genentech research capabilities.
The thesis can fail if the oncology franchise erodes faster than pipeline replacement, obesity pipeline fizzles, diagnostics faces pricing pressure, drug pricing regulation compresses margins, or the Swiss franc appreciates and hits reported earnings.
Thomas Schinecker (CEO since 2023) and Severin Schwan (Chairman) have maintained R&D leadership and capital discipline. Management has restocked the pipeline through Carmot, Spark, and Poseida acquisitions, but the hard question is whether these can sustain growth over the next decade.
Roche sits at the center of precision medicine, the aging population wave, and hospital diagnostic automation. The industry trend is structurally favorable, though drug pricing pressure and biosimilar competition are persistent headwinds.
At roughly 20.9x TTM earnings and 16.5x forward earnings with a ~3% dividend yield, the valuation is reasonable for a mature pharma but does not offer a wide margin of safety. A fair setup needs pipeline visibility and stable diagnostics growth.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ROG ADR price | $51.90 close on July 10, 2026 | Yahoo Finance RHHBY quote | July 13, 2026 |
| Market capitalization | $331.5 billion, verified as $51.90 x 6,387,283,236 ADR equivalent shares | financial_rigor.py market cap verification | July 13, 2026 |
| 2024 revenue (CHF) | CHF 62.39 billion | Roche 2024 Finance Report | July 13, 2026 |
| 2024 net income (CHF) | CHF 9.19 billion | Roche 2024 Finance Report | July 13, 2026 |
| TTM revenue (USD) | $63.36 billion | Yahoo Finance key statistics | July 13, 2026 |
| TTM net income (USD) | $12.88 billion | Yahoo Finance key statistics | July 13, 2026 |
| Cash and equivalents | $15.49 billion as of most recent quarter | Yahoo Finance balance sheet data | July 13, 2026 |
| Levered free cash flow (TTM) | $11.03 billion | Yahoo Finance cash flow data | July 13, 2026 |
| Revenue mix, 2024 | Pharmaceuticals ~75%, Diagnostics ~25% | Roche 2024 Annual Report | July 13, 2026 |
| Moving averages and momentum | 50-day MA $51.27, 200-day MA $50.37, RSI 52.42, ADX 8.95 | Barchart technical analysis | July 13, 2026 |
| Valuation math | 20.93x TTM PE, 7.91x PB, 5.23x PS, 30.0x P/FCF, 2.99% dividend yield from financial_rigor.py | financial_rigor.py valuation verification | July 13, 2026 |
This ROG AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 13, 2026 and can be wrong. Roche Holding AG is listed on the SIX Swiss Exchange under ticker ROG; the price data used in this analysis is from the US ADR (RHHBY) which is a proxy for the economic value of the Swiss-listed shares.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
